Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26102167 | 1.00 | SYK (0.52) | SYKPPARACTSKATMCTSS | |
| SCHEMBL30104803 | 0.91 | PPARA (0.52) | SYKPPARACTSKATMCTSS | |
| SCHEMBL24383269 | 0.90 | SYK (0.58) | SYKPPARACTSKATMCTSS | |
| SCHEMBL8972112 | 0.83 | SYK (0.58) | SYKCTSKATMCTSSCTSL | |
| SCHEMBL12203687 | 0.83 | SYK (0.58) | SYKCTSKATMCTSSCTSL | |
| SCHEMBL21895801 | 0.83 | ATM (0.53) | CTSKATMCTSSCTSLCTSB | |
| SCHEMBL27179575 | 0.81 | SYK (0.46) | SYKPPARAATMCTSSMAPT | |
| SCHEMBL13640158 | 0.81 | PPARA (0.59) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL25369502 | 0.81 | MAPT (0.60) | SYKPPARACTSSMAPTLMNA | |
| SCHEMBL25369496 | 0.81 | MAPT (0.60) | SYKPPARACTSSMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-05-14 | — | — | US | disclosed |
| WO-2023074847-A1 | NOVEL SPIRO COMPOUND | 田辺三菱製薬株式会社 | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | TRHR, NR3C2, THRB | SYK 3786/4885PPARA 908/4885CTSK 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.